Annovis Bio, Inc. (NYSE:ANVS) Receives $37.00 Consensus Price Target from Brokerages

Annovis Bio, Inc. (NYSE:ANVS) has received an average recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $37.00.

Separately, D. Boral Capital reaffirmed a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th.

Annovis Bio Trading Down 3.4 %

Annovis Bio stock opened at $1.59 on Monday. The company’s 50-day moving average is $1.61 and its two-hundred day moving average is $4.47. Annovis Bio has a 1 year low of $1.11 and a 1 year high of $20.00. The company has a market cap of $22.56 million, a PE ratio of -0.36 and a beta of 1.51.

Annovis Bio (NYSE:ANVS) last posted its earnings results on Friday, March 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). During the same period in the prior year, the business posted ($0.43) earnings per share. Research analysts forecast that Annovis Bio will post -2.19 EPS for the current year.

Institutional Investors Weigh In On Annovis Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of ANVS. JPMorgan Chase & Co. bought a new position in Annovis Bio in the third quarter valued at $31,000. Two Sigma Investments LP bought a new position in shares of Annovis Bio in the fourth quarter valued at about $55,000. XTX Topco Ltd acquired a new stake in Annovis Bio during the fourth quarter worth approximately $59,000. Atria Wealth Solutions Inc. acquired a new stake in Annovis Bio during the 4th quarter worth approximately $65,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Annovis Bio in the third quarter valued at about $76,000. Institutional investors and hedge funds own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.